Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 4/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DGKA | P23743 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28985348 | 0.94 | NAAA (0.54) | NAAAEPHX2L3MBTL1MAPTMAPK1 | |
| SCHEMBL5606107 | 0.90 | NAAA (0.44) | NAAAEPHX2ALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL8714110 | 0.84 | SMYD3 (0.40) | NAAAALDH1A1ATML3MBTL1NPSR1 | |
| SCHEMBL8714112 | 0.84 | SMYD3 (0.40) | NAAAALDH1A1ATML3MBTL1NPSR1 | |
| SCHEMBL3252087 | 0.82 | KMT2A (0.50) | NAAAALDH1A1ATML3MBTL1TDP1 | |
| SCHEMBL19569796 | 0.82 | KMT2A (0.50) | NAAAALDH1A1ATML3MBTL1TDP1 | |
| SCHEMBL3251414 | 0.82 | KMT2A (0.50) | NAAAALDH1A1ATML3MBTL1TDP1 | |
| SCHEMBL3256401 | 0.82 | KMT2A (0.50) | NAAAALDH1A1ATML3MBTL1TDP1 | |
| SCHEMBL3248382 | 0.80 | KMT2A (0.51) | NAAAALDH1A1ATML3MBTL1TSHR | |
| SCHEMBL5605614 | 0.80 | NAAA (0.37) | NAAAEPHX2ALDH1A1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2922845-B1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL INC (US) | 2018-06-20 | — | — | EP | disclosed |
| US-7196051-B2 | Process for the preparation of cyclohexyloxyacetic alkyl esters | SYMRISE GMBH & CO. KG (DE) | 2007-03-27 | — | — | US | disclosed |
| US-20030109415-A1 | Process for the preparation of cyclohexyloxyacetic alkyl esters | SYMRISE AG (DE) | 2003-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109415-A1 | Process for the preparation of cyclohexyloxyacetic alkyl esters | FAAH, HAAO, HACL2 | NAAA 35/4885EPHX2 159/4885ALDH1A1 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.